Home|New Products||||Technical support

CD19 antibody mouse specific - HS-439 017

CD19 is a B-lymphocyte antigen
Rat monoclonal purified IgG
Cat. No.: HS-439 017
Amount: 100 µg
Price: $415.00
Cat. No. HS-439 017 100 µg purified IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 100 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.
Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications
 
WB: 1 : 250 gallery  
ICCgallery  
IHC: 1 : 200 gallery  
IHC-P: 1 : 100 gallery  
IHC-Fr: 1 : 200 (see remarks) gallery  
Clone 26D7E5
Subtype IgG2b (κ light chain)
Immunogen Synthetic peptide corresponding to AA 527 to 547 from mouse CD19 (UniProt Id: P25918)
Reactivity Reacts with: mouse (P25918).
No signal: human (P15391), rat.
Other species not tested yet.
Remarks

IHC-Fr: PFA and MeOH fixation are recommended.

Data sheet hs-439_017.pdf
Cat. No.: HS-439 017
Amount: 100 µg
Price: $415.00

Chromogenic double staining for CD19 (DAB) and CD3e (RED) visualized T-cell and B-cell populations in the mouse spleen

Background

CD19 (Cluster of Differentiation 19) is a B cell-restricted signal-transduction molecule that plays an important role in the regulation of development, activation, and differentiation of B-lymphocytes. CD19 is considered as a biomarker for B-cells because of its continued expression from very early B cell development stages, being evident already on pro-B cells and on all later B cell stages, until plasma cell terminal differentiation, when its expression is lost. In complex with CD21 (complement receptor-2), CD81 and CD225 (Leu-13), CD19 functions as a dominant signaling receptor on the surface of mature B cells (1). CD19 is instrumental in B cell homeostasis and lowers the threshold of B cell receptor crosslinking necessary to effect B-cell activation and sustain proliferation upon antigen encounter (2). Dysregulated CD19 expression has been implicated in several autoimmune diseases and CD19 is expressed in most acute lymphoblastic leukemias (ALL), chronic lymphocytic leukemias (CLL) and other B cell lymphomas (3). Therefore, CD19 has gained attention as a potential target in the therapy of B-cell malignancies (4).